Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

DSpace Repository

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Author: Powles, Thomas; Plimack, Elizabeth R.; Soulieres, Denis; Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot, Frederic; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J.; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife, L. Rhoda; Atkins, Michael B.; Rini, Brian, I
Tübinger Autor(en):
Bedke, Jens
Published in: Lancet Oncology (2020), Bd. 21, H. 12, S. 1563-1573
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(20)30436-8
ISSN: 1474-5488
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)